Genpact
G
33.65
+0.20
+0.60%
Genpact
US · G
#2004 by market cap
Listed 1970
33.65
+0.20
+0.60%
Live - 5344 symbols - heartbeat 482s ago
· 2026-10-07 20:02
After-hours
33.25
-1.19%
- Market cap
- 5.63B
- P/E (TTM)i
- 10.01
- P/Bi
- 2.16
- EPSi
- 3.13
- Div yieldi
- 2.12%
- 52W posi
- 33%
Reader sentiment
Are you bullish or bearish on G?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Fair
- Altman Z-Score is 2.87, in the 1.8-3.0 "grey zone".
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +6.56% YoY
Margins
- Gross margin
- 36.04%
- Operating margin
- 14.97%
- Net margin
- 10.88%
Key ratios & quality
- Enterprise valuei
- 6.03B
- PEG ratioi
- 0.62
- Altman Z-Scorei
- 2.87
PEG uses trailing P/E against the 3-year net income growth rate (16.06%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3.00B | 3.52B | 3.71B | 4.02B | 4.37B | 4.48B | 4.77B | 5.08B |
| Gross profit | 1.08B | 1.23B | 1.29B | 1.43B | 1.54B | 1.57B | 1.69B | 1.83B |
| Selling & admin expenses | 693.87M | 794.90M | 789.85M | 865.72M | 938.39M | 913.06M | 967.15M | 1.05B |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 382.86M | 436.86M | 463.09M | 509.16M | 555.96M | 626.67M | 702.06M | 760.29M |
| Pretax profit | 362.02M | 399.42M | 400.48M | 483.13M | 465.24M | 602.22M | 676.82M | 730.15M |
| Tax | 80.76M | 94.54M | 92.20M | 113.68M | 111.83M | -29.03M | 163.15M | 177.65M |
| Net profit | 281.26M | 304.88M | 308.28M | 369.45M | 353.40M | 631.26M | 513.67M | 552.49M |
| Basic EPS | 1 | 2 | 2 | 2 | 2 | 3 | 3 | 3 |
| Diluted EPS | 1.45 | 1.56 | 1.57 | 1.91 | 1.88 | 3.41 | 2.85 | 3.13 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 1.21B | 1.25B | 1.29B | 1.32B | 1.30B | 1.34B |
| Gross profit | 428.99M | 450.07M | 469.66M | 482.29M | 471.67M | 490.34M |
| Selling & admin expenses | 241.08M | 266.39M | 262.11M | 277.13M | 270.34M | 294.13M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 183.70M | 179.40M | 199.38M | 197.81M | 198.58M | 192.94M |
| Pretax profit | 175.22M | 176.74M | 189.35M | 188.83M | 193.99M | 190.88M |
| Tax | 44.37M | 44.02M | 43.52M | 45.74M | 46.00M | 45.15M |
| Net profit | 130.85M | 132.72M | 145.83M | 143.09M | 147.99M | 145.74M |
| Basic EPS | 1 | 1 | 1 | 1 | 1 | 1 |
| Diluted EPS | 0.73 | 0.75 | 0.83 | 0.82 | 0.86 | 0.86 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 1.36B | 1.55B | 1.75B | 1.92B | 1.78B | 1.89B | 2.08B | 2.66B |
| Cash & ST investments | 368.40M | 467.10M | 680.44M | 899.46M | 646.77M | 583.67M | 671.61M | 1.20B |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 3.53B | 4.45B | 4.87B | 4.98B | 4.59B | 4.81B | 4.99B | 5.84B |
| Total current liabilities | 976.31M | 910.21M | 1.20B | 1.31B | 1.10B | 1.32B | 963.74M | 1.60B |
| Short-term debt | 330.29M | 170.91M | 358.08M | 463.57M | 246.78M | 503.39M | 87.43M | 437.69M |
| Long-term debt | 975.65M | 1.34B | 1.31B | 1.27B | 1.25B | 824.72M | 1.20B | 1.17B |
| Total liabilities | 2,125,263,000.00 | 2,765,013,000.00 | 3,039,284,000.00 | 3,078,136,000.00 | 2,762,656,000.00 | 2,557,321,000.00 | 2,597,542,000.00 | 3,293,866,000.00 |
| Total equity | 1.40B | 1.69B | 1.83B | 1.90B | 1.83B | 2.25B | 2.39B | 2.55B |
| Retained earnings | 438.45M | 648.66M | 741.66M | 732.47M | 780.01M | 1.09B | 1.24B | 1.39B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 1.94B | 2.14B | 2.21B | 2.66B | 2.41B | 2.17B |
| Cash & ST investments | 561.62M | 663.26M | 740.76M | 1.20B | 928.08M | 517.39M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 4.89B | 5.31B | 5.36B | 5.84B | 5.62B | 5.41B |
| Total current liabilities | 791.74M | 1.39B | 1.46B | 1.60B | 1.43B | 1.09B |
| Short-term debt | 88.82M | 524.97M | 437.47M | 437.69M | 439.37M | 97.58M |
| Long-term debt | 1.19B | 833.37M | 827.05M | 1.17B | 1.16B | 1.15B |
| Total liabilities | 2,441,897,000.00 | 2,721,069,000.00 | 2,819,622,000.00 | 3,293,866,000.00 | 3,142,046,000.00 | 2,808,299,000.00 |
| Total equity | 2.45B | 2.59B | 2.54B | 2.55B | 2.48B | 2.60B |
| Retained earnings | 1.27B | 1.35B | 1.37B | 1.39B | 1.44B | 1.50B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 339.51M | 427.89M | 584.31M | 694.28M | 443.67M | 490.81M | 615.42M | 812.86M |
| Depreciation & amortization | 103.72M | 128.71M | 159.84M | 167.57M | 129.52M | 103.99M | 96.25M | 94.96M |
| Free cash flow | 179.09M | 319.13M | 503.94M | 637.03M | 389.28M | 432.04M | 530.19M | 724.33M |
| Dividends paid | -57.10M | -64.67M | -74.21M | -80.48M | -91.84M | -100.01M | -108.47M | -117.75M |
| Stock buybacks / issuance | -154.16M | -30.02M | -137.11M | -298.22M | -214.08M | -225.50M | -252.67M | -283.05M |
| Ending cash balance | 368.40M | 467.10M | 680.44M | 899.46M | 646.77M | 583.67M | 648.25M | 853.84M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 40.44M | 177.37M | 308.36M | 286.70M | -23.54M | 72.44M |
| Depreciation & amortization | 21.21M | 21.51M | 26.20M | 26.03M | 20.85M | 20.55M |
| Free cash flow | 17.86M | 152.76M | 288.88M | 264.84M | -54.98M | 49.94M |
| Dividends paid | -29.78M | -29.62M | -29.29M | -29.05M | -31.77M | -31.55M |
| Stock buybacks / issuance | -62.99M | -30.01M | -90.02M | -100.03M | -69.99M | -50.02M |
| Ending cash balance | 561.62M | 663.26M | 740.76M | 853.84M | 578.08M | 517.39M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 19.94 | 19.71 | 17.50 | 19.80 | 18.98 | 30.99 | 22.15 | 22.37 |
| ROA %i | 8.08 | 7.64 | 6.61 | 7.50 | 7.39 | 13.44 | 10.49 | 10.20 |
| ROIC %i | 11.61 | 10.84 | 9.42 | 10.59 | 10.59 | 18.27 | 14.49 | 14.48 |
| 5-year avg ROE %i | 18.68 | 19.68 | 19.48 | 19.27 | 19.19 | 21.40 | 21.88 | 22.86 |
| EBIT margin %i | 13.68 | 12.79 | 12.31 | 13.46 | 11.97 | 14.93 | 15.87 | 15.82 |
| FCF / sales %i | 5.97 | 9.06 | 13.59 | 15.84 | 8.91 | 9.65 | 11.12 | 14.26 |
| Current ratioi | 1.39 | 1.70 | 1.45 | 1.47 | 1.61 | 1.44 | 2.16 | 1.66 |
| Quick ratioi | 1.19 | 1.54 | 1.31 | 1.37 | 1.50 | 1.30 | 1.97 | 1.55 |
| Debt / assetsi | 37.05 | 41.16 | 40.75 | 40.20 | 37.01 | 31.28 | 28.98 | 30.20 |
| LT debt / equityi | 69.60 | 98.43 | 88.74 | 80.99 | 79.48 | 44.46 | 56.82 | 52.04 |
| Interest coveragei | 8.46 | 8.87 | 8.12 | 9.29 | 9.01 | 10.08 | 9.51 | 10.93 |
| Revenue CAGR (3Y) %i | 6.83 | 11.05 | 10.67 | 10.26 | 7.48 | 6.47 | 5.83 | 5.14 |
| Net income CAGR (3Y) %i | 5.46 | 4.45 | 5.73 | 9.52 | 5.05 | 26.99 | 11.61 | 16.06 |
| FCF CAGR (3Y) %i | -12.27 | 7.48 | 20.87 | 52.65 | 6.85 | -5.00 | -5.94 | 23.00 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 22.21 | 21.86 | 22.32 | 22.37 | 23.12 | 22.45 |
| ROA %i | 10.95 | 10.27 | 10.31 | 10.20 | 10.84 | 10.87 |
| ROIC %i | 14.60 | 13.81 | 14.31 | 14.48 | 14.94 | 15.28 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 16.00 | 16.01 | 15.93 | 15.82 | 16.01 | 16.05 |
| FCF / sales %i | 12.33 | 11.39 | 12.82 | 14.26 | 12.62 | 10.45 |
| Current ratioi | 2.45 | 1.53 | 1.51 | 1.66 | 1.69 | 2.00 |
| Quick ratioi | 2.26 | 1.42 | 1.41 | 1.55 | 1.56 | 1.81 |
| Debt / assetsi | 29.50 | 28.86 | 26.64 | 30.20 | 31.30 | 26.13 |
| LT debt / equityi | 55.25 | 38.92 | 38.97 | 52.04 | 53.27 | 50.56 |
| Interest coveragei | 9.63 | 9.98 | 10.75 | 10.93 | 10.65 | 10.60 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Diversified
- High Tech and Manufacturing is the largest reported line at 39.03% of revenue, across 3 reported segments.
- No single line clears half of revenue; Consumer and Healthcare is next at 34.92%, spreading the business across more than one real driver.
Revenue breakdown most recent period
Business
High Tech and Manufacturing39.03%
Consumer and Healthcare34.92%
Financial services26.04%
Quote time 2026-10-07 20:02:43 · For reference only, not investment advice and not tailored to your situation.